Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sumatriptan intranasal - Paratek Pharmaceuticals

Next Previous
Drug Profile

Sumatriptan intranasal - Paratek Pharmaceuticals

Alternative Names: AVP-825; ONZETRA Xsail; OptiNose sumatriptan

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OptiNose AS
  • Developer Avanir Pharmaceuticals; Paratek Pharmaceuticals
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 21 May 2025 OptiNose has been acquired and merged into Paratek Pharmaceuticals
  • 06 Jun 2022 Currax Pharmaceuticals terminates a phase III trial in Migraine (In adolescents) in USA due to insufficient data collection in eDiary for analysis (Intranasal) (NCT03338920)
  • 15 Sep 2020 Sumatriptan intranasal is still in phase III trials for Migraine (In adolescents) in USA (Intranasal) (NCT03338920)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top